ID | 1176 |
Name of the vaccine | CTH522 |
Microbe | Bacteria |
Disease name | Chlamydia |
Name of bacteria | Chlamydia trachomatis |
Type of vaccine | Recombinant |
Nucleic acid content | DNA |
Age | Women of 18 to 45 years |
Description of the vaccine | Recombinant protein subunit adjuvanted vaccine. |
Name of the manufacturer | Statens Serum Institut |
Name of the manufacturing country | United Kingdom |
Year of manufacture | 2017 |
Clinical Phase status | Clinical - Phase 1 |
Bacterial strain | Gram-negative bacteria, coccoid or rod shape. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Four vaccinations. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Prevents chlamydia. |
Export | NA |
Approval | NA |
Adjuvant | CAF01, aluminium hydroxide |
Repurposing | NA |
Side effects of vaccine | Mild local injection-site reactions. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 31416692 |
Clinical trial number | NCT02787109 |
Reference | https://www.precisionvaccinations.com/vaccines/cth522-chlamydia-vaccine |
Other name | NA |
Additional Links | NA
|